juice-email-cli 2.4.12 → 2.4.14
This diff represents the content of publicly available package versions that have been released to one of the supported registries. The information contained in this diff is provided for informational purposes only and reflects changes between package versions as they appear in their respective public registries.
- package/edm/elabscience/series/literature/default/juice.yaml +3 -2
- package/edm/elabscience/series/literature/default/snippet.html +3 -1
- package/edm/elabscience/templates/standard/template.html +8 -0
- package/edm/procell/series/literature/default/juice.yaml +3 -2
- package/edm/procell/series/literature/default/snippet.html +3 -1
- package/edm/procell/templates/standard/template.html +3 -1
- package/package.json +1 -1
|
@@ -11,7 +11,7 @@
|
|
|
11
11
|
# ─── 模板变量（Mustache 语法）────────────────────────────────────────────────
|
|
12
12
|
variables:
|
|
13
13
|
overview:
|
|
14
|
-
image: https://elabcomfile.oss-us-west-1.aliyuncs.com/edm/202605211020/
|
|
14
|
+
image: https://elabcomfile.oss-us-west-1.aliyuncs.com/edm/202605211020/overview.webp
|
|
15
15
|
title: "Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial"
|
|
16
16
|
link: https://www.nature.com/articles/s41591-026-04366-x
|
|
17
17
|
publicationDate: April 29 2026
|
|
@@ -21,7 +21,8 @@ variables:
|
|
|
21
21
|
keywords: Immune Thrombocytopenia (ITP), Nicotinamide Mononucleotide (NMN), CD38-NAD<sup>+</sup> Axis
|
|
22
22
|
|
|
23
23
|
information:
|
|
24
|
-
image:
|
|
24
|
+
image:
|
|
25
|
+
- https://elabcomfile.oss-us-west-1.aliyuncs.com/edm/202605211020/information.webp
|
|
25
26
|
content: "This study identifies the CD38-NAD<sup>+</sup> axis as an immunometabolic checkpoint in ITP. Anti-CD38 antibodies deplete NAD<sup>+</sup>, driving M1 macrophages and FcγRI upregulation, which increases platelet phagocytosis. Restoring NAD<sup>+</sup> via CD38 inhibition or NMN reprograms macrophages to a resting state and blocks platelet destruction without affecting humoral immunity. In 25 refractory ITP patients, low-dose NMN (450 mg bid × 2 weeks) was well tolerated: 20% achieved platelets ≥50×10<sup>9</sup>/L, and 52% maintained response at week 8, with stable immunoglobulin levels. Thus, targeting CD38-NAD<sup>+</sup> metabolism offers a non-antibody-depleting therapeutic strategy."
|
|
26
27
|
link: https://www.procellsystem.com/resources/publications
|
|
27
28
|
buttonText: View More Publications
|
|
@@ -63,7 +63,9 @@
|
|
|
63
63
|
|
|
64
64
|
<tr>
|
|
65
65
|
<td rowspan="2" style="padding-right: 12px;" class="image-box align-middle">
|
|
66
|
-
|
|
66
|
+
{{#information.image}}
|
|
67
|
+
<img src="{{.}}" />
|
|
68
|
+
{{/information.image}}
|
|
67
69
|
</td>
|
|
68
70
|
<td class="h-0 {{#information.link}}pb-24{{/information.link}}">
|
|
69
71
|
<p>{{information.content}}</p>
|
|
@@ -11,7 +11,7 @@
|
|
|
11
11
|
# ─── 模板变量（Mustache 语法）────────────────────────────────────────────────
|
|
12
12
|
variables:
|
|
13
13
|
overview:
|
|
14
|
-
image: https://pri-cella.oss-ap-southeast-1.aliyuncs.com/edm/202604211419/
|
|
14
|
+
image: https://pri-cella.oss-ap-southeast-1.aliyuncs.com/edm/202604211419/overview.webp
|
|
15
15
|
title: "Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial"
|
|
16
16
|
link: https://www.nature.com/articles/s41467-026-70340-3
|
|
17
17
|
publicationDate: April 29 2026
|
|
@@ -21,7 +21,8 @@ variables:
|
|
|
21
21
|
keywords: Immune Thrombocytopenia (ITP), Nicotinamide Mononucleotide (NMN), CD38-NAD<sup>+</sup> Axis
|
|
22
22
|
|
|
23
23
|
information:
|
|
24
|
-
image:
|
|
24
|
+
image:
|
|
25
|
+
- https://pri-cella.oss-ap-southeast-1.aliyuncs.com/edm/202604211419/information.webp
|
|
25
26
|
content: "This study identifies the CD38-NAD<sup>+</sup> axis as an immunometabolic checkpoint in ITP. Anti-CD38 antibodies deplete NAD<sup>+</sup>, driving M1 macrophages and FcγRI upregulation, which increases platelet phagocytosis. Restoring NAD<sup>+</sup> via CD38 inhibition or NMN reprograms macrophages to a resting state and blocks platelet destruction without affecting humoral immunity. In 25 refractory ITP patients, low-dose NMN (450 mg bid × 2 weeks) was well tolerated: 20% achieved platelets ≥50×10<sup>9</sup>/L, and 52% maintained response at week 8, with stable immunoglobulin levels. Thus, targeting CD38-NAD<sup>+</sup> metabolism offers a non-antibody-depleting therapeutic strategy."
|
|
26
27
|
link: https://www.procellsystem.com/resources/publications
|
|
27
28
|
buttonText: View More Publications
|
|
@@ -63,7 +63,9 @@
|
|
|
63
63
|
|
|
64
64
|
<tr>
|
|
65
65
|
<td rowspan="2" style="padding-right: 12px;" class="image-box align-middle">
|
|
66
|
-
|
|
66
|
+
{{#information.image}}
|
|
67
|
+
<img src="{{.}}" />
|
|
68
|
+
{{/information.image}}
|
|
67
69
|
</td>
|
|
68
70
|
<td class="h-0 {{#information.link}}pb-24{{/information.link}}">
|
|
69
71
|
<p>{{information.content}}</p>
|
|
@@ -619,7 +619,9 @@
|
|
|
619
619
|
<tbody>
|
|
620
620
|
<tr>
|
|
621
621
|
<td colspan="4" class="banner image-box">
|
|
622
|
-
<
|
|
622
|
+
<a href="https://www.procellsystem.com/">
|
|
623
|
+
<img src="https://pri-cella.oss-ap-southeast-1.aliyuncs.com/edm/header.webp" alt="Procell" />
|
|
624
|
+
</a>
|
|
623
625
|
</td>
|
|
624
626
|
</tr>
|
|
625
627
|
|
package/package.json
CHANGED